“Any sufficiently advanced technology is indistinguishable from magic”
Arthur C. Clarke
History of electrospray technology
When it began
Electrohydrodynamic atomization (EHDA), also called electrospray, has been studied for centuries starting in the late 1500s when William Gilbert (1544-1603) first observed how a drop of water deformed into a cone in the presence of an electric field.
Since the 1990s electrospray has been successfully employed in applications across a broad range of industries, from biomedical, to nano-materials to food packaging to the aerospace industry.
Gilbert’s application of electrospray for pulmonary delivery
Gilbert is developing the next generation of soft mist inhaler based on electrospray technology to improve treatment for patients with difficult to treat lung conditions.
The inhaler uses Gilbert’s proprietary electrospray technology based on electro hydrodynamic atomization or EHDA, a technology which uses electronic fields to atomize liquids into monodispersed droplets.
Gilbert’s smart precision inhaler creates an ultra-fine soft mist, which the patient should be able to inhale effortlessly and without coordination difficulties.
Furthermore, the droplet size can be customized, enabling targeting of the aerosol medication to desired regions of the lungs, which has the potential to improve the efficacy and safety of treatments.
Gilbert is developing a new soft mist inhaler based on electrospray technology
Want to keep up-to-date with Gilbert?
Gilbert has been making substantial progress in the development of it’s company and technology over the last few years. A clear roadmap has been defined for the next coming years.
The unique IP of Gilbert
Gilbert considers strong intellectual property to be a cornerstone of its business, and strives, on an ongoing basis, to ensure both freedom to operate and robust and enduring patent protection for its technologies and products in the major markets.
To that end, Gilbert has a portfolio of both issued and pending patents with validity extending as far as 2040 should all pending patents issue.
Redefining treatment for lung patients.
Want to know more?